A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Japanese Subjects to Assess the Safety, Pharmacokinetics and Immunogenicity of CR8020 Following Single Intravenous Administration
Phase of Trial: Phase I
Latest Information Update: 29 Mar 2019
Price : $35 *
At a glance
- Drugs CR 8020 (Primary)
- Indications Influenza A virus infections
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 21 Mar 2019 Planned End Date changed from 1 Apr 2014 to 1 Jan 2014.
- 21 Mar 2019 Status changed from not yet recruiting to discontinued.
- 24 Dec 2013 New trial record